1h Free Analyst Time
The irritable bowel syndrome market is forecasted to grow by USD 1.93 billion during 2023-2028, accelerating at a CAGR of 9.3% during the forecast period. The report on the irritable bowel syndrome market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of ibs, growing awareness and diagnosis of ibs, and rising global healthcare expenditure.
The irritable bowel syndrome market is segmented as below:
By Type
- IBS-D
- IBS-C
- IBS-M
By Drug Class
- Antibiotics
- Guanylate cyclase-C agonists
- Mu-opioid receptor agonists
- Chloride channel activators
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the irritable bowel syndrome market covers the following areas:
- Irritable Bowel Syndrome Market sizing
- Irritable Bowel Syndrome Market forecast
- Irritable Bowel Syndrome Market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Type
9 Market Segmentation by Drug Class
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global irritable bowel syndrome market: Abbott Laboratories, AbbVie Inc., Alfasigma Spa, Astellas Pharma Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline Plc, Ironwood Pharmaceuticals Inc, Johnson and Johnson Services Inc., Mallinckrodt Plc, Nestle Health Science S.A., Novartis AG, Pfizer Inc., RedHill Biopharma Ltd., Sanofi SA, Sebela Pharmaceuticals Inc., Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd..Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing number of drug approvals."
According to the report, one of the major drivers for this market is the increasing prevalence of ibs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- AbbVie Inc.
- Alfasigma Spa
- Astellas Pharma Inc.
- AstraZeneca Plc
- Bausch Health Companies Inc.
- Bayer AG
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline Plc
- Ironwood Pharmaceuticals Inc
- Johnson and Johnson Services Inc.
- Mallinckrodt Plc
- Nestle Health Science S.A.
- Novartis AG
- Pfizer Inc.
- RedHill Biopharma Ltd.
- Sanofi SA
- Sebela Pharmaceuticals Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
